Independent research tool — not a government agency. Official notices govern.Refreshed

Assistance Listing 16.754

Harold Rogers Prescription Drug Monitoring Program

Department of Justice · Office of Justice Programs

Assistance Listing 16.754, “Harold Rogers Prescription Drug Monitoring Program,” is a federal program administered by Department of Justice. It provides grant assistance. GrantsJunction currently tracks 0 open, 0 forecasted and 13 closed opportunities under this listing. The agency reported $5.19M in obligations for fiscal year 2025.

Program objective

Program goal(s) name: Strengthen states and territories’ ability to maintain and enhance PDMPs and data integration to inform clinical decision making and abuse of prescription drugs. Program goal(s) description: Support state and local governments to encourage the use of PDMPs, integration of PDMP data with health information exchanges (HIE), electronic health records (EHR), or pharmacy dispensing systems (PDS), and engaging with tribal entities and rural areas where integration rates may be lower to improve clinical decision making and detecting and preventing the diversion and abuse of pharmaceutically controlled substances such as opioids and other prescription drugs. This program helps to break the cycle of drug addiction and violence by reducing the demand for, use, and the illegal trafficking of controlled substances. Program objective(s) name: Strengthen capacity and facilitate use of prescription drug data Program objective(s) description: Strengthen capacity of PDMPs to share information on prescribing, dispensing, and use of prescription drugs within and between states using preferred method of choice, and via RxCheck Hub; Facilitate use of PDMP data to support law enforcement efforts, allocation of substance use disorder treatment and prevention resources, and sound clinical decision making among prescribers; and Design, implement, and advance initiatives to improve linkage, analysis, reporting, usage, and sharing of PDMP derived data.

As published in the SAM.gov Assistance Listing.

Current opportunities under 16.754

No open or forecasted opportunities are currently posted under this listing. Programs often post notices on an annual cycle — see recently closed opportunities below for timing.

Eligible applicants (program level)

  • Other

Program-level eligibility from SAM.gov. Each funding notice sets its own requirements.

Reported obligations by fiscal year

Historical data · not a prediction
FY24$6M
FY25$5.19M
FY26— est.

Range and average of financial assistance (from the listing): See the current fiscal year’s NOFO available at the Office of Justice Programs web site ( https://www.ojp.gov/funding/explore/current-funding-opportunities).

Source: SAM.gov Assistance Listing 16.754. Hatched bars are agency estimates. These totals do not indicate approval rates.

Recently closed under 16.754

Closed opportunities under 16.754
OpportunityStatusAward rangeClosesALN
ClosedUp to $2MSep 23, 202616.754
ClosedUp to $2MOct 27, 202516.754
ClosedUp to $7MSep 17, 202416.614, 16.738, 16.754, 16.815, 16.835
ClosedUp to $1MAug 9, 202416.754
ClosedUp to $11.1MJul 14, 202316.041, 16.044, 16.610, 16.614, 16.738, 16.752, 16.754
ClosedUp to $2MJun 29, 202316.754
ClosedUp to $5MJun 17, 202216.754
ClosedUp to $1.4MJun 15, 202216.754
ClosedUp to $1.5MMar 19, 202116.754
ClosedUp to $2MMay 6, 202016.754

Frequently asked questions

What is ALN 16.754?

16.754 is the Assistance Listing Number for “Harold Rogers Prescription Drug Monitoring Program.” Assistance Listing Numbers (formerly CFDA numbers) identify federal assistance programs; individual grant opportunities reference the listing they are funded under.

Who can apply under ALN 16.754?

The SAM.gov listing names these applicant types: Other. Each funding notice under the program sets its own eligibility, so check the specific opportunity.

How much funding does 16.754 provide?

The agency reported $5,190,964 in obligations for FY2025 in the SAM.gov Assistance Listing. These are program-wide totals reported by the agency, not a prediction of future awards.